Safety and PK of GSK2269557 in Healthy Japanese Subjects

Phase 1, randomised, double-blind trial of nemiralisib in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by GSK. Primary endpoints: Number of subjects with any adverse event(s) (AE) and serious adverse event(s) (SAE) up to 37 days, Number of subjects having abnormal clinical laboratory parameters up to 22 days and 11 more. Started Oct 2016; status: completed.